Clene Inc (CLNN)

$8.52 +1.22 (16.71%)
Market Cap 73.51M
Revenue (ttm) 340,000.00
Net Income (ttm) -39.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,588.24%
Debt to Equity Ratio -0.54
Volume 217,300
Avg Vol 134,320
Day's Range N/A - N/A
Shares Out 10.07M
Stochastic %K 36%
Beta 0.72
Analysts Strong Sell
Price Target $30.43

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 801 676 9695
Website: clene.com
Address:
6550 South Millrock Drive, Suite G50, Salt Lake City, United States
Mulhollandr
Mulhollandr Nov. 14 at 9:10 PM
$CLNN imo it’s either this Monday or first week of December we hear news. Nothing happens on turkey week.
1 · Reply
bosch49
bosch49 Nov. 14 at 9:09 PM
$CLNN
0 · Reply
fibonacci1170
fibonacci1170 Nov. 14 at 8:06 PM
$CLNN company is taking its leisurely time. The NfL data better show statistically significant difference between the drug and placebo. And this will 10x to $90
2 · Reply
ransoms2121212
ransoms2121212 Nov. 14 at 6:31 PM
$CLNN just look at those institutions gobbling up shaky leaves
0 · Reply
Scoops1212
Scoops1212 Nov. 14 at 5:11 PM
$CLNN
1 · Reply
Takeover24
Takeover24 Nov. 14 at 4:29 PM
$CLNN Quite the reversal so far today. Had an order in to buy 9,000 shares at $6.58. Actually hit $6.59 as the low for day but did not fill my order. I already own a ton of shares but was happy adding more at such a gift price (well gift in the sense that the slight delay in timing did not justify such big drop as I still thin the data will be positive and the company will proceed with the NDA discussions with the FDA)! Original order placed on: 11/14/2025 10:21:34 AM EST Reference #: MNZ 2139 Order Status: Open All fields are required Transaction Symbol CLNN Quantity 9,000 Order Type Limit Limit Price 6.58 Duration Day Account Type Yes, this order was recommended by my investment professional/representative. CLENE INC COM NEW NASDAQ Listed $7.7301 x 250FINRA ADF 0.4301 (5.89%)More Info Bid $7.55 x 100 NASDAQ Ask $7.90 x 100 NASDAQ Last Traded: Nov 14 11:25 AM ET
1 · Reply
Chris150
Chris150 Nov. 14 at 4:18 PM
$CLNN For anyone interested about CNM-Au8 physics, the VISIONARY-MS trial and some ALS things, you can take a look at this interview of Rob and Mark about a year ago (yes a bit old interview). There are some fundamentals there that might be valuable. https://www.youtube.com/watch?v=Xn9Shp2ssNo
1 · Reply
Mulhollandr
Mulhollandr Nov. 14 at 4:13 PM
$CLNN could a rebound be afoot?!🧐
0 · Reply
ransoms2121212
ransoms2121212 Nov. 14 at 3:05 PM
$CLNN Strong volume this morning, also seeing strong support in the $6.80 range--I think the swing traders have exited but not seeing any institutions exiting > 10g filings for will be interesting to watch
0 · Reply
neuroinvestor3
neuroinvestor3 Nov. 14 at 12:07 PM
$CLNN Why do they want to focus on cognition endpoint over other MS symptoms? It worries me that they were talking to the FDA only about the older Visionary-ms P2 trial. Was the more recent Repair-ms P2 trial not as good? They have data on improved visual acuity, walking speed, etc. I thought CNM-Au8 improved overall EDSS score? Also, is there data on lesion and relapse reduction that would be part of a P3 trial? "In September 2025, the Company held a Type B end-of-Phase 2 meeting with the FDA, during which Clene and the FDA reviewed results from the Phase 2 VISIONARY-MS trial and explored proposed endpoints for the planned Phase 3 study focusing on cognition improvement as an adjunct to standard-of-care MS therapies. The FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness to considering other potential primary endpoints, including cognition, to evaluate broader treatment effects.
1 · Reply
Latest News on CLNN
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

Nov 13, 2025, 8:00 AM EST - 2 days ago

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Emerging Growth Conference

Oct 20, 2025, 8:30 AM EDT - 26 days ago

Clene to Present at the Emerging Growth Conference

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Oct 15, 2025, 8:30 AM EDT - 4 weeks ago

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Sep 25, 2025, 8:00 AM EDT - 7 weeks ago

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Sep 4, 2025, 8:30 AM EDT - 2 months ago

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 2 months ago

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 14, 2025, 8:38 AM EDT - 3 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Canaccord 45th Annual Growth Conference

Aug 5, 2025, 8:30 AM EDT - 3 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 30, 2025, 8:00 AM EDT - 4 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Jun 9, 2025, 9:00 AM EDT - 5 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

May 7, 2025, 8:00 AM EDT - 6 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 8:30 AM EDT - 8 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 24, 2025, 8:00 AM EDT - 8 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 12, 2025, 8:00 AM EDT - 8 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Clene to Present at the 37TH Annual Roth Conference

Mar 6, 2025, 8:30 AM EST - 9 months ago

Clene to Present at the 37TH Annual Roth Conference

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 27, 2025, 9:15 AM EST - 9 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Feb 25, 2025, 8:00 AM EST - 9 months ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Dec 10, 2024, 8:30 AM EST - 1 year ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Clene Announces 1-for-20 Reverse Stock Split

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

Clene to Present at Upcoming May Conferences

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Feb 29, 2024, 8:00 AM EST - 1 year ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 11:25 AM EST - 2 years ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Dec 14, 2023, 8:36 AM EST - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Nov 7, 2023, 8:00 AM EST - 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Clene to Present at Upcoming September Conferences

Aug 30, 2023, 8:20 AM EDT - 2 years ago

Clene to Present at Upcoming September Conferences

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Jun 21, 2023, 9:20 AM EDT - 2 years ago

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Mulhollandr
Mulhollandr Nov. 14 at 9:10 PM
$CLNN imo it’s either this Monday or first week of December we hear news. Nothing happens on turkey week.
1 · Reply
bosch49
bosch49 Nov. 14 at 9:09 PM
$CLNN
0 · Reply
fibonacci1170
fibonacci1170 Nov. 14 at 8:06 PM
$CLNN company is taking its leisurely time. The NfL data better show statistically significant difference between the drug and placebo. And this will 10x to $90
2 · Reply
ransoms2121212
ransoms2121212 Nov. 14 at 6:31 PM
$CLNN just look at those institutions gobbling up shaky leaves
0 · Reply
Scoops1212
Scoops1212 Nov. 14 at 5:11 PM
$CLNN
1 · Reply
Takeover24
Takeover24 Nov. 14 at 4:29 PM
$CLNN Quite the reversal so far today. Had an order in to buy 9,000 shares at $6.58. Actually hit $6.59 as the low for day but did not fill my order. I already own a ton of shares but was happy adding more at such a gift price (well gift in the sense that the slight delay in timing did not justify such big drop as I still thin the data will be positive and the company will proceed with the NDA discussions with the FDA)! Original order placed on: 11/14/2025 10:21:34 AM EST Reference #: MNZ 2139 Order Status: Open All fields are required Transaction Symbol CLNN Quantity 9,000 Order Type Limit Limit Price 6.58 Duration Day Account Type Yes, this order was recommended by my investment professional/representative. CLENE INC COM NEW NASDAQ Listed $7.7301 x 250FINRA ADF 0.4301 (5.89%)More Info Bid $7.55 x 100 NASDAQ Ask $7.90 x 100 NASDAQ Last Traded: Nov 14 11:25 AM ET
1 · Reply
Chris150
Chris150 Nov. 14 at 4:18 PM
$CLNN For anyone interested about CNM-Au8 physics, the VISIONARY-MS trial and some ALS things, you can take a look at this interview of Rob and Mark about a year ago (yes a bit old interview). There are some fundamentals there that might be valuable. https://www.youtube.com/watch?v=Xn9Shp2ssNo
1 · Reply
Mulhollandr
Mulhollandr Nov. 14 at 4:13 PM
$CLNN could a rebound be afoot?!🧐
0 · Reply
ransoms2121212
ransoms2121212 Nov. 14 at 3:05 PM
$CLNN Strong volume this morning, also seeing strong support in the $6.80 range--I think the swing traders have exited but not seeing any institutions exiting > 10g filings for will be interesting to watch
0 · Reply
neuroinvestor3
neuroinvestor3 Nov. 14 at 12:07 PM
$CLNN Why do they want to focus on cognition endpoint over other MS symptoms? It worries me that they were talking to the FDA only about the older Visionary-ms P2 trial. Was the more recent Repair-ms P2 trial not as good? They have data on improved visual acuity, walking speed, etc. I thought CNM-Au8 improved overall EDSS score? Also, is there data on lesion and relapse reduction that would be part of a P3 trial? "In September 2025, the Company held a Type B end-of-Phase 2 meeting with the FDA, during which Clene and the FDA reviewed results from the Phase 2 VISIONARY-MS trial and explored proposed endpoints for the planned Phase 3 study focusing on cognition improvement as an adjunct to standard-of-care MS therapies. The FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness to considering other potential primary endpoints, including cognition, to evaluate broader treatment effects.
1 · Reply
BabyZhenya
BabyZhenya Nov. 14 at 11:40 AM
$CLNN I TOLD YOU
1 · Reply
_MAGAT
_MAGAT Nov. 14 at 1:56 AM
$CLNN YUUUUUGE turd stock
0 · Reply
Scoops1212
Scoops1212 Nov. 14 at 1:50 AM
$CLNN
0 · Reply
NoFearHere
NoFearHere Nov. 13 at 10:33 PM
$CLNN SPRTS=6.14@100dma🎯 +5.8+ 5.35 +4.91 🎯
0 · Reply
Takeover24
Takeover24 Nov. 13 at 10:15 PM
$CLNN Let's look on the brightside, at least this big drop today was not the result of bad data which of course would have been a lot worse. Assuming there is no connection between the delay and the likelihood of positive results, then this is just a near term blip and we still have hope (with the story unchanged from when the share price hit $13.50 a few weeks ago (other than the slight delayed timeline).
2 · Reply
neuroinvestor3
neuroinvestor3 Nov. 13 at 10:14 PM
$CLNN brutal day... I had a feeling we would be getting "unfulfilling" news... Why is Clene leadership not able to get a partner to help get though P3's and stabilize cash runway? I hope whatever they need can come from their multibillionaire CoB, Dave Matlin. Unless we get some good news quick, there's no reason this doesn't drop back into the $3-5 range.
3 · Reply
Woodman7
Woodman7 Nov. 13 at 9:24 PM
$CLNN - the road to commercialization of a new drug is a long and treacherous process. I’m looking at today as a relatively minor set back and certainly NOT worthy of the change in stock price from what we knew yesterday to what we know today.
1 · Reply
biotrade123
biotrade123 Nov. 13 at 9:00 PM
$CLNN wheres the bottom?
1 · Reply
Ravery
Ravery Nov. 13 at 7:17 PM
$CLNN I guess it is clearer now that the run up in share price was macro driven. Some of us, myself included, felt the rise in clnn's stock price was fundamentally driven and there was a leak. A lot of small bios have been getting slammed lately. Likely just rotation and short scum smelling blood in the water.
2 · Reply
Mulhollandr
Mulhollandr Nov. 13 at 6:58 PM
$CLNN just a nibble but added 130 shares
1 · Reply
Bobfree
Bobfree Nov. 13 at 5:47 PM
$CLNN biomarker analysis "completion planned shortly" - the only thing that I really care about remains a wait and see. Other than that no red flags in how they are handling finances (actually overall moderately bullish in this regard). All good.
1 · Reply
Stocktwitmk
Stocktwitmk Nov. 13 at 4:05 PM
$CLNN
0 · Reply